Trump’s 100% Tariff Threat: Is India’s Pharma Industry at Risk? | Explained | N18G

[00:00:00]President Trump is threatening a tariff on generic drugs. The term zero tariff for 2 years from August 1st, then 100% for a year, then 200% after that. The goal, reshore generic manufacturing to America and improve national drug supply security. Now, why should India care?

[00:00:18]Because India is the generic backbone of America's medicine cabinet. 90% of all US prescriptions by volume are generics and India supplies roughly 40% of them.

[00:00:31]That's a $10 billion export business.

[00:00:34]India also runs over 650 US FDA approved plants, the most outside America itself.

[00:00:42]And the reason it works, manufacturing here costs 30 to 50% less than in the US with labor costs a large part of the pie being 35 to 50% cheaper.

[00:00:55]So, who's exposed? Several frontline names. Lupin, Aurobindo and Glenmark each draw around 42% of their sales from the US. Zydus close behind at round 40%.

[00:01:08]Dr. Reddy's at round 34%. Sun Pharma at round 29% and Cipla at round 22%. Many already have US capacity with Aurobindo and Sun Pharma building up US presence further through recent acquisitions and Lupin with a $250 million Florida investment. All this could work in these companies favor.

[00:01:34]Now, here's the number that should worry Washington more than Delhi. Industry voices say generic manufacturing in the US runs five to 10 times more expensive depending on the molecule, raising costs by 25 to 30% for US production to even be commercially viable, prices would possibly need to rise 50% Take paracetamol a box of 100 generic tablets cost around $2 to $5 in the US today versus $7 to $15 for the branded version of it. Shift generic production home and that same box could climb to around four to seven and a half dollars.

[00:02:18]And that gap only widens as the drug complexity increases.

[00:02:24]Now the impact Industry watchers are drawing on the branded Pharma playbook. Some dilution as deadlines approached. Analysts expect generics to follow a similar script.

[00:02:36]CAPEX announcements as a hedge but not a full manufacturing exodus. There's also a political catch. Trump's term ends in Jan 2029 and this two-year runway ends right around the 2028 US election. But there's no guarantee policy reverses if the political wind shift and in that scenario smaller and mid-size generic companies serving the US could see a far bigger hit.

[00:03:05]Industry stands right now. Wait and watch. No formal order, no fine print and a clear sense that Indian Pharma has to lobby its case before the clock runs out. Bottom line, yes it is a sentiment negative, economically improbable at scale and for the American consumer this could be a tariff that ends up taxing their own medicine cabinet.

[00:03:40]>> Hey, thank you for watching this on CNBC TV [music] 18. Hope you liked it. For more such interesting news and updates follow CNBC TV 18 on all the social media platforms.